Skip to main
CI

Cigna (CI) Stock Forecast & Price Target

Cigna (CI) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 33%
Buy 60%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Cigna Group is poised for substantial growth, driven by its Evernorth segment, which enhances patient satisfaction and lowers costs while also improving health outcomes. The company projects a margin recovery within its Healthcare segment, with an anticipated 100 basis points recapture by 2027, largely expected in 2026, which aligns with its long-term growth target of 7%-10% for the Healthcare segment. Additionally, Cigna's strong free cash flow will support ongoing capital deployment to expand service offerings, thereby augmenting core growth trends and reinforcing a favorable risk/reward valuation outlook.

Bears say

Cigna Group is anticipating a decline in its Evernorth adjusted operating income (AOI) for 2026, primarily due to pharmacy benefit management (PBM) margin headwinds, with estimates suggesting a drop from $3,506 million in 2025 to approximately $2,749 million in 2026. The transition to a rebate-free PBM model is projected to reduce earnings by $500 million to $600 million, further contributing to a negative financial outlook. Additional risks include potential client losses, slower biosimilar adoption, and the overall pressure on margins due to lower-priced contracts, which are likely to hinder revenue growth in a challenging commercial market.

Cigna (CI) has been analyzed by 15 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 60% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cigna and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cigna (CI) Forecast

Analysts have given Cigna (CI) a Buy based on their latest research and market trends.

According to 15 analysts, Cigna (CI) has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $352.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $352.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cigna (CI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.